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Dendritic cells (DCs) have been attracting attention in cancer immunotherapy because
of their role in inducing and modulating effective immune responses. Besides the direct
contact with other cell types and the secretion of cytokines, it is becoming clear that
nanovesicles, such as exosomes (Exo), secreted by DCs also have a role in their function.
Conversely, tumor-derived Exo carry antigens and have been used as a source of spe-
cific stimulus for the immune response against tumors. At the same time, several works
have shown that different cells types incorporate DC-derived Exo (DC-Exo), resulting in
modifications of their phenotype and function. Since DC-Exo carry many of the immune
function-associated molecules of DCs, their incorporation by tumor cells could turn tumor
cells into immunogenic targets.We have, therefore, treated human breast adenocarcinoma
cells (SK-BR-3) with DCs-Exo and used these to stimulate previously SK-BR-3-primed CD3+
T-cells. Sensitized T-cells cultured with DC-Exo-treated tumor cells showed a significantly
higher percentage of IFN-γ-secreting cells (as measured by ELISPOT), when compared to
the frequency of cells responding to non-DC-Exo-treated cells. These data show that the
incorporation of DC-Exo by the tumor cells increased their ability to activate T-cells for a
possibly more effective response, thus showing that DC-Exo may become another tool in
cancer immunotherapy.
Keywords: dendritic cells, exosomes, cancer immunotherapy, immunomodulation, tumor immune response, tumor
cell immunogenicity
INTRODUCTION
Dendritic cells (DCs) are key players in the immune response;
they are able to capture antigens with their pattern-recognition
receptors, process and present them to naïve T-cells, inducing
their activation (1, 2), thus, building an essential bridge between
innate and adaptive responses. The central role that DCs play in the
immune response, and the possibility of their in vitro generation
has pathways for immunotherapy, in particular, for the treatment
of cancer (3–8). However, the use of DCs outside clinical studies is
hampered by the difficulties inherent to cell therapy strategies and,
furthermore, in the case of DCs specifically against cancer, also by
the compromised function of these cells in cancer patients (9–
12). Not surprisingly, therefore, the general appraisal of DC-based
strategies against cancer has been negative (10, 13). On the other
hand, tumor cells do present potentially immunogenic antigens
(14), which, when recognized by T-cells in immunotherapeutic
approaches, seem to be associated with lasting tumor remissions
(15). Therefore, strategies aimed at exposing tumor antigens to
the immune system, bypassing the need for very active DCs, but
in such a way that it leads to the establishment of T-cell responses,
would be a potentially effective approach to harness the immune
system to fight cancer.
In this context, therefore, it is relevant to note that, as most
other cell types, DCs secrete nanovesicles, among which are the
exosomes (Exo) (16–19). Exo are secreted vesicles that originate
in the late endosomal compartment and result from the fusion of
multivesicular bodies with the plasma membrane (20) and which
can be acquired by other cells, at least in ex vivo cell cultures (21–
24). These nanovesicles contain membrane proteins and genetic
material, which, upon capture by other cells, contribute to the
intercellular communication in the body (25–27). In fact, mem-
brane traffic between DCs via Exo has been shown to occur (22),
and Exo-carried antigens can be reprocessed for presentation or
simply transferred directly to the membrane, in a process called
cross-dressing (28). Furthermore, Exo transfer has been reported
also to happen between cells of different types (25, 29, 30). Indeed,
we demonstrated previously that Exo originated from DCs may
be incorporated by tumor cells in vitro and that these tumor cells,
after treatment with DC-derived Exo (DC-Exo), expressed mol-
ecules involved with antigen presentation, such as HLA-DR and
CD86 (21).
Therefore, in this paper, we investigated if DC-Exo have the
capacity to turn tumor cells into better targets for the immune
system. We show that, indeed, DC-Exo treated tumor cells are able
to induce tumor-sensitized T-cells to secrete higher levels of IFN-γ
than non-DC-Exo-treated tumor cells. This observation supports
our hypothesis and indicates that, as a minimum, DC-Exo used
in cancer immunotherapy may act as a means to sensitize tumor
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cells to other immune effectors, thus enhancing the effectiveness
of different immunotherapeutic approaches.
EXOSOMES FROM DENDRITIC CELLS AND THEIR ROLE IN
ANTI-TUMOR RESPONSE
Raposo et al. (20) were the first to describe that Exo (originat-
ing from EBV-transformed B cells) contained functional MHC-II
molecules, which carried peptides to which the cells were exposed
and were able to stimulate peptide-specific CD4+ T-cells. From
this initial observation, many others indicated a role for Exo in
immune response to various stimuli, including tumors. Actually,
in a mouse model, DC-Exo, containing class I major histocompat-
ibility antigens (MHC-I) complexed with tumor-derived peptides
were shown to induce a cytotoxic T lymphocyte (CTL) response,
which inhibited tumor growth and rejected established tumors
(16, 19, 22), probably due to the incorporation of the Exo by
host DCs in vivo (31). Also, in a clinical trial, ascites-derived
Exo administered with GM-CSF induced CEA-specific-T lympho-
cytes (17), confirming the potential of Exo to carry and deliver
effectively tumor antigens, as observed in various other settings
(16, 18).
EXOSOMES FROM DCs COULD TURN TOLEROGENIC TUMOR
CELLS INTO IMMUNOGENIC TARGETS?
Though the generation of effective T lymphocytes responses is one
of the main goals of cancer immunotherapy and the use of DC-
Exo has been shown to be a means to achieve this goal, directly
(19, 32, 33) or indirectly, by their incorporation by the recipients
DCs (31, 33), the effectiveness of these immune effector cells
depends on other factors. Actually, this is well illustrated by the fact
that tumor-specific immune responses are frequently detected in
patients who, nonetheless, have a progressive disease. This obser-
vation, essentially, has challenged for a long time, the potential of
immunotherapy to control cancer. However, more recent experi-
mental and clinical data have led to the realization that the immune
system can, indeed, control and, probably, eliminate tumors, if
“properly” engaged (34). In various clinical settings, this “proper”
engagement of the immune system has been achieved, so far, either
by the elimination of immune checkpoints, with monoclonal anti-
bodies directed to immunoregulatory surface molecules (35), or
by “arming” T lymphocytes with tumor-specific chimeric recep-
tors, a strategy that, likewise, bypasses physiological controls of the
immune response (36). However, these strategies depend, on one
hand, on the existence of tumor cell targets already recognized by
the immune effectors and, on the other hand, on the establishment
of strong enough interactions between the immune effectors and
the tumor targets.
In this perspective, our observation that tumor cells incorpo-
rate DC-Exo and, thereafter, express various surface molecules
involved in the interaction between antigen-presenting cells and T
lymphocytes (21) gains a new relevance. Not only could DC-Exo-
treated tumor cells gain antigen-presenting capabilities, which
might induce de novo anti-tumor responses, but also such cells
could become better targets to any immune effector cell, either
naturally induced by the presence of the tumor in the patient or
induced by immunotherapeutic approaches (Figure 1).
FIGURE 1 | Hypothetical scheme of the tumor microenvironment
changed by treatment with Exo from immunogenic DCs (DC-Exo).
(A) Low immunogenic tumor cells and immature DCs (iDCs) cannot induce
specific-T lymphocyte response and, if such effectors do exist, they are not
sufficiently stimulated by the tumor cells. (B) Enrichment of the tumor
microenvironment with Exo-DC modifies tumor cells, enhances their
immunogenic potential and turns them into better targets for any immune
effector cell. Furthermore, immature DCs present in the tumor could also
capture DC-Exo, acquire a mature phenotype and migrate to draining lymph
nodes, where they could set up and amplify the immune response.
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To test this hypothesis, we sensitized human CD3+ T-cells
against the breast carcinoma cell line SK-BR-3. Monocyte-derived
DCs were pulsed with tumor cell Exo for 24 h, in the pres-
ence of IL-1, IL-6, TNF-α, and PGE2. Tumor-Exo were used as
antigen source, since it was shown that they induce anti-tumor
responses more efficiently than irradiated tumor cells, apoptotic
bodies, or tumor cells lysate (37). Next, these DCs were co-
cultured with autologous T-cells, in the presence of IL-2 and
IL-7 for 14 days. After that, tumor-Exo sensitized T-cells were
exposed to SK-BR-3 cells that were treated or not with DCs-Exo
(Exo Control in the figure) or Exo obtained from DCs exposed
to tumor Exo (Exo Tex in the figure). After 2 days, the IFN-γ-
producing T-cells were quantified by ELISPOT (Figure 2). It is
interesting to note that SK-BR-3 cells, alone, seemed to induce
some cytokine production by sensitized T-cells, but this produc-
tion was not statistically different from that of T-cells cultured
alone. However, the treatment of the tumor cells with Exo (both
Exo control and Exo Tex) increased this response to a signif-
icant level. It is noteworthy that these responses were modest,
but nevertheless, significant, thus in agreement with our hypoth-
esis: tumor cells treated with Exo derived from DCs became
better targets for an already existing immune effector cell pop-
ulation – those T-cells that had been sensitized in vitro against
the tumor cells, but whose response was not strong enough to
raise above the background. Furthermore, when the Exo were
obtained from DCs that were treated with tumor cell exosomes
(Tex), the enhancement of IFN-γ production seemed to be even
higher. Though speculative, it is possible to recognize, here, an
antigenic enrichment of the targets, since cells may load their
FIGURE 2 | IFN-γ-production by tumor-sensitizedT-cells is enhanced
when tumor target cells are treated with Exo obtained from DCs. Cells
of the human breast adenocarcinoma cell line SK-BR-3 were pre-treated or
not with Exo (130µg/106 cells), obtained from control DCs (Exo Control) of
from DCs exposed to tumor cell Exo (Exo Tex) and co-cultured for 2 days
with previously sensitized CD3+ T-cells (autologous to the DC source of the
Exo). After that, the cells were harvested and the number of
IFN-γ-producing cells was quantified by ELISPOT. T-cells pre-sensitization
was obtained by co-culture with autologous tumor cell exosome-treated
DCs, for 14 days, in presence of IL-2 and IL-7. Average and SD of the number
of cytokine-producing cells are represented (n=6; ANOVA *p< 0.0028,
flowing Dunnett’s Multiple Comparison Test).
Exo not only with their co-stimulatory molecules but also with
antigen-loaded MHC complexes (20), which would be captured
by the tumor cells, hence turning these into even better targets for
the antigen-specific-T-cells.
DISCUSSION
Tumor cells are poorly immunogenic and this has hampered the
development of effective cancer immunotherapy. Yet, new insights
on the role of different components of the immune response have
broadened the field, so that, today, effective immune strategies to
treat cancer are not longer seen as a remote possibility, but as a con-
crete breakthrough. However, though such approaches, as the use
of checkpoint inhibitors or chimeric antigen receptor-transfected
T-cells have reached astounding successes in some situations, the
need for improvement is still pressing.
As depicted in Figure 1, even the presence (naturally or by
transfer) of tumor-specific immune effectors within the tumor
microenvironment may not be enough to hamper tumor growth
and development. An immunosuppressive environment and tar-
gets that are poor in both antigens and co-stimulatory mole-
cules may decrease significantly the effectiveness of tumor-specific
responses. Therefore, any strategy that achieves the enhancement
of tumor cell antigenicity or, even better, immunogenicity, should
make it easier to control the disease in cancer patients. Such
strategies could do so either by directly inducing tumor-specific
responses, if the increase in tumor immunogenicity is strong
enough, and, if not, by sensitizing tumors to borderline responses
that, by themselves are not able to control the disease, but in face
of more readily recognizable targets would do it.
Here, we tested the hypothesis that DC-Exo would perform
such a role, increasing tumor cell antigenicity/immunogenicity.
The transfer of information between cells via Exo is being rec-
ognized as a significant phenomenon for the body intercellular
communication (38, 39), since Exo can interact with several cells
types (26) and transfer information by means of fusion with the
plasma membrane (40). Furthermore, this transfer seems not to
be random, but controlled by molecules expressed by Exo and the
“target cells,” as we have shown for the incorporation of DC-Exo
by tumor cells, where the incorporation of DC-Exo by tumor cells
was directly proportional to the expression CD9 molecules by the
latter (21). In other setting, Exo capture, by the monocytes lineage,
THP-1, has been shown to depend on toll like receptors, TLR-2 and
TLR-4, leading to activation of NF-κB and STAT3, and to cytokine
secretion (41).
Since Exo carry several molecules of their cells of origin
(27), they would be a possible way to load tumor cells with
antigen presentation-associated molecules from DCs. Indeed,
we did observe the transfer of HLA-DR and CD86 molecules
from DC-Exo to tumor cells (21). Furthermore, when we ana-
lyzed tumor cells treated with DC-Exo, we noticed that these
had an increased expression of ICAM-molecules, which could
facilitate their interaction with T lymphocytes, since the inter-
action between ICAM-I and LFA on lymphocytes accentuates
TCR/MHC/peptide interaction (32).
Thus, we tested if SK-BR-3 tumor cells treated with DC-Exo
would be able to induce a T-cell response more effectively. Accord-
ingly, we observed that treatment of the tumor cell line with
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DC-Exo enhanced their ability to activate tumor-sensitized T-
cells to secrete IFN-γ. We chose this cytokine because of its role
in anti-tumor immune responses (42, 43) being associated with
both CD8 and CD4 T-cell responses (44, 45), and essential for
priming long-lived memory CD8+ T-cells (46, 47). It must be
recognized, however, that the response we obtained though sig-
nificant, when compared to the non-stimulated T-cell response,
was modest, showing just a tendency to statistical significance,
when compared to the response induced by the non-Exo-treated
cells. This is, actually, in agreement with our hypothesis, since
the expected action of the nanovesicles would be to enhance just
enough the sensitivity of the targets to already existing immune
effector mechanisms – and not, necessarily, the induction of new
responses. Another issue that should be noted is that the clin-
ical application of such a strategy would be restricted to situ-
ations where tumors might be directly accessed, since the sys-
temic inoculation of Exo would hardly deliver them to the tumor
cells, but, rather, to other cells along their distribution through
the body.
On the positive side, however, it is worth noting that this strat-
egy, of treating tumor cells with DC-Exo, eliminates the need
of specific tumor antigens identification, since it transfers to the
patients’ immune system this task. Through their association with
DC-derived molecules, tumor antigens that would be poorly pre-
sented otherwise, would have their “visibility” increased, and,
therefore, would be more likely to become effective targets of the
patient’s immune response. Furthermore, the local injection of
these DC-Exo could allow them to be captured also by the patient’s
DCs in the tumor microenvironment. This would have a positive
effect in the tumor immune response since in cancer patients,
tumor-infiltrating DCs have functional deviations, maintaining
an immature phenotype (9, 48–51). Thus, if these DCs incorpo-
rate Exo derived from immunogenic DCs, a phenomenon shown
to occur (22), they might even become able to induce the response
of tumor-specific naïve T lymphocytes.
Finally, even if the modifications of tumor cells immunogenic-
ity caused by their incorporation of DC-Exo are not enough to give
rise to de novo tumor-specific immune responses in the patients,
they would, as we show here, turn the tumor cells into more effec-
tive targets to immune effectors induced by any other means. Thus,
it is possible to suggest that treatment of tumors with DC-Exo
could contribute to the effectiveness of any immunotherapeutic
strategy, be it active, like vaccination protocols or passive, like
the transfer of tumor-specific effectors. In face of this hypoth-
esis and the data we obtained, we believe that this approach
should receive consideration and be further investigated, in order
to evaluate better its possible effectiveness, and to determine the
most effective Exo doses, the length of its effect on tumor cells,
and, mainly, the precise activation status of the DC, used as Exo
source.
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